Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol in moderate to severe COPD
NCT00396604Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 second at 24 hours. Started Oct 2006; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00396604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396604.